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Background: To assess the sensitivity, specificity and turnaround time of flow cytometric analysis on
brain biopsies compared to histology plus immunohistochemistry analysis in tumors with clinical suspi-
cion of lymphoma.
Methods: All brain biopsies performed between 2010 and 2015 at our institution and analyzed by
both immunohistochemistry and flow cytometry were included in this retrospective study. Immunohisto-
chemistry was considered the gold standard.
Results: In a total of 77 biopsies from 71 patients, 49 lymphomas were diagnosed by immunohisto-
chemistry, flow cytometry results were concordant in 71 biopsies (92.2%). We found a specificity and
sensitivity of flow cytometry of 100% and 87.8%, respectively. The time between the biopsy and report-
ing the result (turnaround time) was significantly shorter for flow cytometry, compared to immunohisto-
chemistry (median: 1 vs. 5 days).
Conclusions: Flow cytometry has a high specificity and can confirm the diagnosis of a lymphoma sig-
nificantly faster than immunohistochemistry. This allows for rapid initiation of treatment in this highly
aggressive tumor. However, since its sensitivity is less than 100%, we recommend to perform histology
plus immunohistochemistry in parallel to flow cytometry. VC 2018 The Authors. Cytometry Part B: Clinical Cytometry
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Primary central nervous system lymphoma (PCNSL) is
a rare non-Hodgkin lymphoma confined to the brain, lep-
tomeninges, eyes, or spinal cord (1). Approximately 3%
of all brain tumors are PCNSL. Secondary central nervous
system lymphoma, or CNS localization of systemic lym-
phoma, occurs most frequently in Burkitt lymphoma (up
to 43%) or in diffuse large B-cell lymphoma (DLBCL)
patients (5–14%, depending on its stage or risk factors)
(2,3). Common presenting symptoms of a CNS lymphoma
are focal neurological deficits, neuropsychiatric symp-
toms, headache, and less typically, seizures (4). MRI
mostly shows single or multiple space occupying lesions,
with homogeneous contrast enhancement. Before starting
treatment, cytological, or histologic confirmation of the
presence of a lymphoma is required. Since clinical deteri-
oration is frequent in both primary and secondary CNS
lymphoma, a rapid diagnosis is preferable. Sometimes a
CNS lymphoma can be diagnosed by vitreous or cerebro-
spinal fluid (CSF) analysis (5). However, a spinal tap may
be contraindicated in space occupying lesions and even if
safely possible, PCNSL is diagnosed on CSF in about 30%
of patients only (6). Consequently, a brain biopsy remains
necessary in the majority of the patients. Similarly, sys-
temic lymphoma may also present with intraparenchyma-
tous lesions, and may present with diagnostic uncertain-
ties requiring histological confirmation. Histology with
immunohistochemistry (IHC) is considered the gold stan-
dard in the analysis of brain biopsies in diagnosing a lym-
phoma. Immunophenotyping by flow cytometry is an
objective and quantitative method ideally suited to iden-
tify small populations of cells with aberrant phenotypes
(7). It is particularly helpful for the detection of small
clonal populations of B-lymphocytes. The technique has
proven its value in the analysis of bone marrow, fine nee-
dle aspiration of lymph nodes and in cerebrospinal fluid
(8–12). In cerebrospinal fluid, the sensitivity increases 2–
3 times (13–17). However, few data defining the added
value and diagnostic accuracy of flow cytometry in brain
biopsies have been published. In our center immunophe-
notyping using eight-color flow cytometry has been uti-
lized in addition to histology with IHC in brain biopsies
since 2010 in brain tumor patients in whom a lymphoma
was suspected, based on clinical and radiological features.
The aim of this study was to determine the added clinical
and diagnostic value of immunophenotyping by flow
cytometry in brain biopsies. Furthermore, since analysis
by flow cytometry is in general much faster than by
immunohistochemistry, we also sought to investigate the
difference in time needed to acquire a diagnosis by these
two techniques.
METHODS
Patients
All brain biopsies performed at the Erasmus University
Medical Center in Rotterdam, the Netherlands, between
January 2010 and December 2015 were retrospectively
extracted from patient and laboratory registries. See Sup-
porting Information Figure S1 for the flowchart of
selecting biopsies. Only biopsies which were analyzed
by both IHC and flow cytometry were included for sta-
tistical analysis. Flow cytometric analysis was routinely
performed when a lymphoma was suspected on radio-
logical grounds. In addition, HIV-status, use of cortico-
steroids, and immunomodulating medication, of all
patients were collected. Turnaround time (time between
biopsy and report of the analysis) was extracted from
patient files or laboratory log. Preliminary results given
to the clinician were not included in our statistical anal-
ysis. The size of the biopsies and the numbers of cells
within the flow cytometric analysis were registered. As
a check for lymphoma patients not included, all patients
with CNS lymphoma diagnosed in the same period in
our center were extracted from the national pathology
database PALGRA. The study was approved of by the
Independent Review Board of our institution.
Neurosurgical Procedures
Brain tissue was collected by image-guided stereotac-
tic biopsies; when a high grade glioma was suspected
patients went for open surgery. The stereotactic biopsies
were framelessly performed using the Medtronic Stealth
TreonTM VertekVR system until 2010 and the BrainlabVR
Varioguide neuronavigation system ever since (18,19).
In general, four biopsies were obtained at the preopera-
tively determined target, as well as two to four more
biopsies at a site proximal to the target on the same
biopsy trajectory. Open biopsies were performed using
image-guided navigation and the operation microscope.
After surgery the collected biopsies were divided for his-
topathology and flow cytometry by the neurosurgeon,
or by the pathologist if all material had initially been
sent to the pathology laboratory. Intra-operative freeze
sections were not performed in most patients to maxi-
mize available tissue for definitive pathology and flow
cytometry.
Histology and Immunohistochemistry
All tumors were classified according to the World
Health Organization (WHO) classification of Tumours of
Haematopoietic and Lymphoid Tissues version 2008 by
conventional histological assessment on 2 mm hematoxy-
lin and eosin (H&E) stained sections and on 4 mm immu-
nohistochemically stained sections. Sections were cut
from formalin-fixed brain tumor tissues, embedded in
paraffin blocks using standard pathology tissue process-
ing procedures (20). For immunohistochemistry, the fol-
lowing primary antibodies were used: CD3, CD5, CD10,
CD19, CD20, CD79a, Bcl-2, Bcl-6, and Mib-1. When
appropriate this panel was extended with one or more
of the following antibodies: BOB-1, MUM1, CD 15,
cyclin D1, Smlgkappa, Smlglambda, CD21, CD23, CD68,
CD138, CD4, GFAP, CD31, CD43, TIA-1, ALK-1, CD8,
and PAX-5. All immunohistochemical procedures using
primary and secondary antibodies and detection sys-
tems, were performed according to the manufacturer’s
recommendations on a Ventana Benchmark Ultra plat-
form (Ventana Medical Systems Inc., Tucson, USA),
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tested and validated according to ISO 15189 standards.
See Figure 1 for an example of a cerebral NHL, analyzed
by histology with immunohistochemistry.
Flow Cytometry
Cell suspensions were generated from a single,
unfixed brain biopsy by gentle manual disaggregation on
a 100 mm strainer using a 10 mL syringe plunger rod
and wash buffer (PBS/BSA 0.5%; not using any
enzymes). The released cells were collected by rinsing
with a total volume of 10 mL wash buffer and washed
twice in 10 mL wash buffer; centrifugation steps were
for 5 minutes at 540g. After the last wash step, the
supernatant was discarded and the pellet of cells was
suspended in wash buffer. Fifty microliters of the cell
suspension were stained using the EuroFlow
Lymphocytosis Screening Tube (LST), according to the
EuroFlow protocol (21,22). The LST contains antibodies
CD20-Pacific Blue (Clone: 2H7; Biolegend), CD4-Pacific
Blue (RPA-T4; Biolegend), CD45-Pacific Orange (HI30;
Invitrogen), CD8-FITC, SmIgk-FITC, CD56-PE, SmIgj-PE
(SLPC mix; Cytognos), CD5-PerCP-Cy5.5 (L17F12, BD
Biosciences, CD19-PC7 (J3–119; Beckman Coulter),
SmCD3-APC (SK7, BD Biosciences), and CD38-APCH7
(HB7; BD Biosciences). Subsequently the suspension
was acquired on a FACSCanto II flowcytometer (BD Bio-
sciences, Erembodegem, BE) using EuroFlow settings
(23). We aimed to acquire at least 5000 B-cells (with a
minimum of 50.000 leukocytes); if this could not be
reached we acquired all available cells in the tube.
Appropriate instrument set-up and staining protocols
were monitored by the EuroFlow QA scheme (24). After
exclusion of debris, doublets and non-hematopoietic
cells (CD45 negative, CD19 negative), which all together
could add up to over 95% of acquired events in some
samples, we defined the presence of a B-NHL population
as a population with a marked shift in the SmIgKappa/
SmIgLambda ratio (<0.7 or >2.8) and/or a clearly aber-
rant immunophenotype (e.g., abnormal expression of Ig,
CD19, CD20, and/or CD38, abnormal (high) forward
scatter). If a B-NHL was detected and sufficient cells
were available, EuroFlow BCLPD tube 1 to 4 were
stained as well. In all cases, the diagnosis of a B-NHL
was based on the results of the LST tube only, the addi-
tional information resulting from the additional BCLPD
tubes was used to further specify the immunophenotype
and to hint to specific B-NHL subtypes. Even though
pathologists and immunologists who evaluated the analy-
ses were not blinded for each other’s conclusion, the
flow cytometry results were reported independently of
histology plus IHC analysis. See Figure 2 for an example
of a cerebral NHL, analyzed by flow cytometry.
Statistical Analysis
To determine the diagnostic value of flow cytometry,
the reports of flow cytometry and immunohistochemis-
try were compared. Morphology plus IHC was consid-
ered the gold standard. In case the results were suspi-
cious for a lymphoma but not conclusive, it was
categorized as ‘no lymphoma’. The turnaround time and
whether the results were available within 24 hours,
were compared between the two techniques using
the Wilcoxon signed-ranks and a McNemar test,
respectively. Differences with respect to use of dexa-
methasone and sample size, between concordant and
discordant groups and between those who had multi-
ple biopsies and who did not were analyzed by Mann-
Whitney U or a Fisher’s Exact test. All analyses were
performed by SPSS Statistics 21.
RESULTS
Between January 2010 and December 2015 77 biop-
sies which have been analyzed by both histology and
flow cytometry, were performed in 71 patients (59%
male) with a median age of 63 (range 15–82). 10% of
FIG. 1. Histology and immunohistochemistry analysis. HE-staining
with diffuse large B-cell lymphoma, activated blast type: brain tissue
(right) with infiltration of blastic cells with large vesicular nuclei with
nucleoli (left). These tumor cells express CD20 (shown in the figure
below), CD79a, BCL-2, BCL-6, and MUM1 and very weak expression
of CD10. [Color figure can be viewed at wileyonlinelibrary.com]
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the patients were immunocompromised, which was
defined as being HIV-infected (one patient) or using sys-
temic immunomodulating treatment (e.g., methotrexate,
azathioprine). Of all CNS lymphoma patients diagnosed
in our hospital between 2010 and 2015 by histology
and IHC, only four were not sent for flow cytometric
analysis. In two cases all material was immediately pre-
served in formalin which made the tissue no longer suit-
able for flow cytometry, in two additional cases lym-
phoma was not considered in the pre-operative
differential diagnosis.
Forty-nine biopsies were diagnosed as brain lym-
phoma by histology and immunohistochemistry; 43 of
these were also diagnosed as lymphoma by flow cytome-
try (Table 1). By flow cytometry, all identified cases
were CD191/CD201; Ig light chain restriction was
observed in most cases (38; 83%) whereas no Ig expres-
sion was detected in nine cases (17%). None of the 28
tissue samples not diagnosed as lymphoma by histology
plus IHC were identified as lymphoma by flow cytome-
try. We thus found a concordance, specificity and sensi-
tivity of immunophenotyping by flow cytometry in brain
biopsies of 92.2% (71/77), 100% (28/28), and 87.8%
(43/49), respectively. The positive predictive value was
100% (43/43) and the negative predictive value was
82.4% (28/34). Numbers of leukocytes (after exclusion
of debris, doublets and non-hematopietic cells) that
could be analyzed by flow cytometric analysis ranged
widely: 9425 (29–207,259), median (range). Although
statistical analysis to compare biopsies with discordant
and concordant results should be interpreted with cau-
tion due to small numbers, no significant differences
were found with respect to sample size (P5 0.06), num-
ber of cells acquired by flow cytometry (P5 0.62), or
corticosteroid use prior to biopsy (P5 0.108). All 6 dis-
cordant cases were DLBCL, without unusual evidence of
necrosis. In 6/71 patients, a second biopsy and in 2/71
FIG. 2. Flow cytometry analysis. Flowcytometric analysis on brain biopsy, showing a cerebral NHLwith the presence of T-cells (11% of leukocytes)
and B-cells (89% of leukocytes). Whereas the T-cells (grey) showed a normal CD4/CD8 ratio (lower row, third plot) and a normal immunophenotype
(CD31/CD451; upper row, second and third), the B-cells (CD191; black) were clearly abnormal, with monotypic Immunoglobulin kappa expression,
low expression of CD45, and light scatter characteristics (FSC and SSC; upper row, first plot) compatible with large cells. The biopsy was stained
with the EuroFlow Lymphocytosis Screening Tube according to EuroFlow procedures.
Table 1
Diagnostic Value of Flow Cytometry on Brain Biopsies
Flow cytometry
Immunohistochemistry
Lymphoma No lymphoma Total
Lymphoma 43 0 43
No lymphoma 6 28a 34
49 28 77
aIncluding 8 cases in which both results were
“inconclusive.”
4 VAN DER MEULEN ET AL.
Cytometry Part B: Clinical Cytometry
patients even a third biopsy was necessary to make a
diagnosis, because of an inconclusive diagnosis in previ-
ous biopsies. Only those biopsies which were investi-
gated by both techniques (6/8) were included in the sta-
tistical analysis. In the biopsies, analyzed by IHC only,
two additional lymphoma were found. Use of corticoste-
roids prior to first biopsy (P5 0.06), size of the biopsy
(P5 0.68) and/or number of cells for flow cytometric
analysis (P5 0.19) were similar in patients with conclu-
sive and inconclusive diagnoses. The 20 patients with-
out a lymphoma were diagnosed with a myriad of dis-
eases: 11 glioblastoma, 1 anaplastic astrocytoma, one
germinoma, one stroke, five infections, and one CLIP-
PERS syndrome (chronic lymphocytic inflammation with
pontine perivascular enhancement responsive to ste-
roids), a rare auto-immune disorder. We found a signifi-
cantly shortened time to reporting of the results (turn-
around time) for flow cytometry, compared to IHC
(Table 2). Furthermore, in 54% of the biopsies the diag-
nosis was provided within 24 hours using flow cytome-
try, compared to 9% using histology plus IHC.
DISCUSSION
In this study, we compared flow cytometry with his-
tology plus IHC on 77 brain biopsies, performed in
patients clinically suspected of having a lymphoma. We
found a high concordance between both techniques
(92.2%) and a specificity and sensitivity of flow cytome-
try by immunophenotyping in brain biopsies of 100%
and 88%, respectively. In six patients with histologically
proven NHL, the presence of a lymphoma could not be
identified by flow cytometry. No factors (e.g., sample
size, use of corticosteroids prior to the biopsy) could be
identified which could explain the missing diagnosis in
flow cytometry. Unlike in CSF or bone marrow analysis
no additional cases of brain lymphoma were identified
by flow cytometry that had not been identified by
immunohistochemistry. We found a significant difference
in turnaround time for the two techniques. After biopsy
a diagnosis was given with a median time of 5 days
(range 0–18) for immunohistochemistry, compared to
median of 1 day (range 0–7) for flow cytometry. In 54%
of the biopsies the presence or absence of a lymphoma
could be confirmed within 24 hours by flow cytometry,
compared to 9% for immunohistochemistry (P< 0.00),
which means that correct treatment could be initiated
within 24 hours. It should be noted that the preliminary
results of the flow cytometric analysis were frequently
reported to the clinician on the day of biopsy. Given the
frequently rapid clinical deterioration in CNS lymphoma
and the negative impact of a lower performance score
on survival, according to the two largest validated prog-
nostic models, (25,26) early diagnosis is may improve
prognosis (27). Similar findings were reported in a
much smaller cohort of 18 stereotactic biopsies recently
(28). Cordone et al. found a significant agreement
between flow cytometry and immunohistochemistry
diagnosis (P5 0.0034). They described a sensitivity and
specificity of flow cytometry by immunophenotyping of
89% and 100%, respectively. In the 2/18 PCNSL biopsies
not identified by flow cytometry more central necrosis
was present, compared to biopsies with concordant
results and both patients used corticosteroids prior to
the biopsy (28). We did not find more central necrosis
in our discordant biopsies and corticosteroid use did not
differ between concordant and discordant pairs. One
other study analyzed flow cytometry on rinse fluid. Even
though rinse fluid from the biopsy needle cannot be
completely compared to brain tissue itself, this study
showed similar results (29). In a small sample, a high
specificity (100%) and sensitivity (75% on rinse fluid and
100% on tissue sample) of flow cytometry in detecting a
brain lymphoma were found. The added value was again
the time in which the flow cytometry could confirm the
diagnosis (63–20 hours, compared to 2–10 days for his-
topathological diagnosis). Because the diagnosis could
be confirmed within 24 hours in 75% of the cases, the
authors recommend to use both techniques, allowing
chemotherapy to commence within 24 hours. In con-
trast with the results of our study and two comparable,
though much smaller studies on brain biopsies, flow
cytometry on bone marrow and CSF allowed identifica-
tion of additional lymphoma cases over cytology. The
sensitivity of cytological analysis of CSF for lymphoma
cells is low (2–32%) (30). Several authors found that
additional flow cytometry on CSF improves the sensitiv-
ity, up to 2–3 fold (13–15). In up to 80%, the lymphoma
cells are detected in the first CSF sample, analyzed by
flow cytometry (15). It is likely that this additional sensi-
tivity of flow cytometry is a result of the low number of
tumor cells available for diagnosis in CSF and bone mar-
row. Corticosteroids can induce apoptosis in lymphoma
cells. This can mask the morphology and can even cause
the tumor to vanish (31–33). In lymph nodes and CSF
samples, flow cytometry can confirm a diagnosis on
samples with a low cell count. We hypothesized that
flow cytometry, being a more sensitive technique, may
be able to recognize lymphoma in patients in whom,
after steroid use, lympholysis had taken place and histol-
ogy plus IHC was negative. Unfortunately, this was not
the case in our series nor in the other two smaller stud-
ies available. Five patients who went for multiple biop-
sies and were diagnosed with brain lymphoma after
Table 2
Time to Diagnosis
Immunohistochemistry
n577
Flow
cytometry
n576
Turnaround
time (days)
5 (0–18) 1 (0–7) P<0.00a
Diagnosis
<24 hours
(biopsies)
7 (9%) 41 (54%) P<0.00b
Median time (range) in days between biopsy and diagno-
sis. Significance was calculated by aWilcoxon signed-ranks
test and bMcNemar Test. In one biopsy the date of reporting
was missing for flow cytometry analysis.
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their second or third biopsy, used corticosteroids prior
to their first (and second) biopsy. In none of these
patients flow cytometry analysis was able to make the
diagnosis when histology plus IHC were non-diagnostic.
Clearly, immunohistochemistry as well as flow cytome-
try analysis can be compromised in patients using corti-
costeroids prior to the biopsy.
The strengths of this study are the comprehensive
clinical and laboratory data in a large, unselected sam-
ple, allowing calculation of the diagnostic and clinical
value of flow cytometry on brain biopsies. To the best
of our knowledge, this is the largest cohort ever
described comparing flow cytometry to immunohisto-
chemistry in brain biopsies. Furthermore, due to our
large population, we were able to show that the nega-
tive effect of corticosteroids on the diagnostic value of
flow cytometry was similar to that on IHC. Even our
series, however, still concerns a relatively small number
of cases. The main drawback of our study is its retro-
spective nature: we may have missed some biopsies,
even though we did a thorough search through all avail-
able databases in our hospital (neurosurgery, flow
cytometry, pathology and neuro-oncology) and the
immunologist and pathologist were not blinded for each
other’s results. Nevertheless the flowcytometric result
was always reported without knowledge of the patho-
logical evaluation. In addition, we did not perform
freeze sections, so comparison with intraoperative diag-
nosis could not be made.
CONCLUSION
Flow cytometry analysis in brain biopsy is a feasible
technique with 100% specificity to confirm the diagnosis
of brain lymphoma in patients suspected for lymphoma
on clinical grounds. The added clinical value is the
speed by which flow cytometry can establish or confirm
the diagnosis, enabling a faster initiation of treatment,
while false positive cases were not identified. Flow
cytometry is complementary to, but not more sensitive
than, histopathology with immunohistochemistry analy-
sis. We recommend to perform flow cytometry and
immunohistochemistry in parallel in brain biopsies, sus-
pected for a lymphoma.
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